一项针对多发性硬化症患者的转移因子与安慰剂的双盲试验。
A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.
作者信息
Collins R C, Espinoza L R, Plank C R, Ebers G C, Rosenberg R A, Zabriskie J B
出版信息
Clin Exp Immunol. 1978 Jul;33(1):1-11.
Abstract
A double-blind trial of the effect of transfer factor on multiple sclerosis patients was carried out. In a series of fifty-six multiple sclerosis patients treated with monthly injections of either transfer factor or placebo for 1 year, no beneficial effect of transfer factor was noted. In addition, none of the immunological and serological parameters studied (measles migration inhibition, measles HI titre or CSF immunoglobulin) changed as a result of transfer factor therapy. Histocompatibility typing and CSF IgG/TP ratios were correlated with the disease activity. Of interest was the finding that the presence of the DW2 antigen, when unassociated with HLA-B7 antigen, appeared to correlate with the mildest form of disease activity.
摘要
进行了一项关于转移因子对多发性硬化症患者疗效的双盲试验。在一组56例多发性硬化症患者中，每月分别注射转移因子或安慰剂，持续1年，未发现转移因子有有益效果。此外，所研究的免疫和血清学参数（麻疹迁移抑制、麻疹血凝抑制滴度或脑脊液免疫球蛋白）均未因转移因子治疗而发生变化。组织相容性分型和脑脊液IgG/TP比值与疾病活动相关。有趣的是，发现当DW2抗原与HLA - B7抗原不相关时，似乎与最轻微形式的疾病活动相关。
相似文献
1
A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.一项针对多发性硬化症患者的转移因子与安慰剂的双盲试验。
Clin Exp Immunol. 1978 Jul;33(1):1-11.
2
Transfer factor as a therapy for multiple sclerosis: a follow-up study.转移因子治疗多发性硬化症：一项随访研究。
Clin Exp Neurol. 1986;22:149-54.
3
Transfer factor is ineffective in amyotrophic lateral sclerosis.转移因子对肌萎缩侧索硬化症无效。
Ann Neurol. 1979 Apr;5(4):385-8. doi: 10.1002/ana.410050413.
4
Studies of HLA antigens in multiple sclerosis.多发性硬化症中人类白细胞抗原的研究。
Boll Ist Sieroter Milan. 1978 Jan 31;56(6):516-30.
5
Transfer factor in treatment of multiple sclerosis.转移因子在多发性硬化症治疗中的应用
Lancet. 1980 Nov 1;2(8201):931-4. doi: 10.1016/s0140-6736(80)92100-5.
6
Association of histocompatibility haplotype HLA-A3-B7 with multiple sclerosis.组织相容性单倍型HLA - A3 - B7与多发性硬化症的关联。
J Immunol. 1976 Nov;117(5 Pt.2):1906-12.
7
[Study of 39 cases of multiple sclerosis (MS) including 2 familial cases. Leukocyte migration inhibition test in the presence of measles antigen with and without levamisole. HL-A typing (SD)].对39例多发性硬化症（MS）患者的研究，其中包括2例家族性病例。在有和没有左旋咪唑存在的情况下，进行麻疹抗原存在时的白细胞迁移抑制试验。HL-A分型（SD）。
Ann Med Interne (Paris). 1977 Oct;128(10):767-72.
8
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.移植后粒细胞集落刺激因子（G-CSF）与安慰剂对T细胞充足的异基因血液移植患者的免疫和临床影响：一项随机双盲研究的结果
Cytotherapy. 2003;5(6):542-52. doi: 10.1080/14653240310003648.
9
Long-term transfer-factor treatment for multiple sclerosis.多发性硬化症的长期转移因子治疗
Lancet. 1978 Apr 22;1(8069):851-3. doi: 10.1016/s0140-6736(78)90194-0.
10
Immunological aspects of multiple sclerosis.多发性硬化症的免疫学方面。
Br J Hosp Med. 1977 Nov;18(5):467-8, 470, 473-6.
引用本文的文献
1
A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients.转移因子对多发性硬化症患者影响的临床与免疫学研究
Clin Exp Immunol. 1981 Mar;43(3):557-64.
2
HLA antigens and progression of multiple sclerosis. Part II.人类白细胞抗原与多发性硬化症的进展。第二部分。
J Neurol. 1983;229(3):167-74. doi: 10.1007/BF00313740.
3
Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.参与硫唑嘌呤多中心试验的多发性硬化症患者的组织相容性抗原。英国和荷兰多发性硬化症硫唑嘌呤试验组。
J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):412-5. doi: 10.1136/jnnp.51.3.412.
4
Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.α干扰素与转移因子治疗多发性硬化症：一项双盲、安慰剂对照试验。澳大利亚多发性硬化症研究组
J Neurol Neurosurg Psychiatry. 1989 May;52(5):566-74. doi: 10.1136/jnnp.52.5.566.
5
HLA antigens and multiple sclerosis in Northern Ireland.北爱尔兰的人类白细胞抗原与多发性硬化症
Ir J Med Sci. 1990 Mar;159(3):68-70. doi: 10.1007/BF02946670.
本文引用的文献
1
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
2
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.多发性硬化症治疗的实验性试验问题：多发性硬化症治疗实验性试验评估小组报告
Ann N Y Acad Sci. 1965 Mar 31;122:552-68. doi: 10.1111/j.1749-6632.1965.tb20235.x.
3
Measles antibodies in multiple sclerosis.多发性硬化症中的麻疹抗体。
Proc Soc Exp Biol Med. 1962 Dec;111:562-6. doi: 10.3181/00379727-111-27855.
4
On the evaluation of disability in multiple sclerosis.关于多发性硬化症残疾情况的评估。
Neurology. 1961 Aug;11:686-94. doi: 10.1212/wnl.11.8.686.
5
Rabbit antibodies to streptococcal carbohydrates. Influence of primary and secondary immunization and of possible genetic factors on the antibody response.抗链球菌碳水化合物的兔抗体。初次免疫和二次免疫以及可能的遗传因素对抗体反应的影响。
J Exp Med. 1969 Apr 1;129(4):809-30. doi: 10.1084/jem.129.4.809.
6
Lymphocytic responses to streptococcal antigens in glomerulonephritic patients.肾小球肾炎患者对链球菌抗原的淋巴细胞反应。
Science. 1970 May 29;168(3935):1105-8. doi: 10.1126/science.168.3935.1105.
7
HL-A antigen frequencies in multiple sclerosis. Significant increase of HL-A3, HL-A10 and W5, and decrease of HL-A12.多发性硬化症中的人类白细胞抗原（HL-A）抗原频率。HL-A3、HL-A10和W5显著增加，HL-A12减少。
Eur Neurol. 1972;7(1):74-8. doi: 10.1159/000114414.
8
Immunochemical quantitation of antigens by single radial immunodiffusion.通过单向辐射免疫扩散法对抗原进行免疫化学定量。
Immunochemistry. 1965 Sep;2(3):235-54. doi: 10.1016/0019-2791(65)90004-2.
9
HL-A antigens and diseases. I. Multiple sclerosis.组织相容性白细胞抗原（HL-A）抗原与疾病。I. 多发性硬化症。
Tissue Antigens. 1973;3(4):243-50. doi: 10.1111/j.1399-0039.1973.tb01002.x.
10
Measles antibody titers of multiple sclerosis patients and their siblings.多发性硬化症患者及其兄弟姐妹的麻疹抗体滴度。
Neurology. 1972 May;22(5):492-9. doi: 10.1212/wnl.22.5.492.
Zotero 插件